B.C. company expands antibody research, production facilities for 2nd time

  • 📰 CHEK_News
  • ⏱ Reading Time:
  • 34 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 55%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

B.C. company expands antibody research, production facilities for second time

Posted: May 24, 2023 1:11PMThe Canadian company that helped develop the first antibody therapy treatment for COVID-19 is more than doubling the size of its planned expansion in Vancouver.

The federal government gave AbCellera $176 million toward the manufacturing plant and is announcing another $225 million today for the research and clinical trial projects.AbCellera senior vice-president Murray McCutcheon says the company’s new campus will be able to take research on antibody therapies from early ideas through to clinical trials.

AbCellera partnered with drug giant Eli Lilly in 2020 to develop Bamlanivimab, which was authorized for use less than a year after the first case of COVID-19 was discovered. The new manufacturing plant is under construction now and is set to be producing antibody therapies for clinical trials starting next year.

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 59. in DE
 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

B.C. company denies misleading First Nation about rail terminal expansion plansThe owner of a rail terminal in British Columbia's Interior says a lawsuit launched by the Bonaparte First Nation is a 'collateral attack' on the company's 'numerous' grants, permits, and licenses to operate the expanding facility.
Herkunft: PGCitizen - 🏆 65. / 51 Weiterlesen »